Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating) major shareholder Medpace Investors, Llc acquired 57,426 shares of Medpace stock in a transaction dated Thursday, September 22nd. The shares were acquired at an average price of $154.59 per share, with a total value of $8,877,485.34. Following the completion of the transaction, the insider now owns 6,483,019 shares of the company's stock, valued at approximately $1,002,209,907.21. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Large shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.

Medpace Investors, Llc also recently made the following trade(s):

• On Monday, September 19th, Medpace Investors, Llc acquired 94,119 shares of Medpace stock. The shares were acquired at an average price of $153.48 per share, with a total value of $14,445,384.12.
• On Tuesday, September 13th, Medpace Investors, Llc bought 62,516 shares of Medpace stock. The stock was purchased at an average price of $157.12 per share, with a total value of $9,822,513.92.

Medpace Stock Performance

Shares of NASDAQ MEDP traded down $9.45 during trading on Friday, hitting $145.38. The company had a trading volume of 624,044 shares, compared to its average volume of 345,257. The company has a market cap of $4.51 billion, a P/E ratio of 24.82 and a beta of 1.47. Medpace Holdings, Inc. has a 52 week low of $126.94 and a 52 week high of $231.00. The business's 50-day moving average is $161.45 and its 200 day moving average is $152.75.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Wasatch Advisors Inc. raised its stake in Medpace by 12.1% during the 1st quarter. Wasatch Advisors Inc. now owns 2,728,392 shares of the company's stock valued at $446,338,000 after purchasing an additional 294,103 shares during the period. Boston Trust Walden Corp raised its stake in Medpace by 38.2% during the 1st quarter. Boston Trust Walden Corp now owns 674,994 shares of the company's stock valued at $110,423,000 after purchasing an additional 186,518 shares during the period. Riverbridge Partners LLC raised its stake in Medpace by 44.1% during the 2nd quarter. Riverbridge Partners LLC now owns 481,404 shares of the company's stock valued at $72,052,000 after purchasing an additional 147,225 shares during the period. Loomis Sayles & Co. L P raised its stake in Medpace by 149.5% during the 4th quarter. Loomis Sayles & Co. L P now owns 233,242 shares of the company's stock valued at $50,763,000 after purchasing an additional 139,767 shares during the period. Finally, Echo Street Capital Management LLC raised its stake in Medpace by 18.4% during the 1st quarter. Echo Street Capital Management LLC now owns 695,336 shares of the company's stock valued at $113,750,000 after purchasing an additional 108,133 shares during the period. Institutional investors own 83.97% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on MEDP. StockNews.com downgraded Medpace from a "buy" rating to a "hold" rating in a research report on Thursday, September 8th. UBS Group began coverage on Medpace in a research report on Wednesday, September 7th. They issued a "sell" rating and a $142.00 target price for the company.

About Medpace

(Get Rating)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Featured Stories

• Get a free copy of the StockNews.com research report on Medpace (MEDP)
• Why Does Tesla Stock Remain Resilient?
• Will Crowdstrike Get A Boost From Increased EPS Guidance?
• Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
• 2 Semiconductor Stocks To Watch For Reversals
• Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.